Ocrelizumab consent

I conducted a telephone consultation with Miss XXX today in order to consent her for treatment with Ocrelizumab. She has already received information about Ocrelizumab.

I explained the potential benefits to include:


 * 1) Reduction in MS relapse rate
 * 2) Reduction of disease progression
 * 3) Reduction in number of new brain lesions seen on MRI scan.

I explained the following risks and/or side effects:


 * 1) Infusion related reactions
 * 2) Increased risk of infections including upper respiratory tract infections
 * 3) Reduced level of antibodies (hypogammaglobulinaemia) which may also increase the risk of infections
 * 4) Slightly increased risk of cancer, in particular, breast cancer.

I explained that there is a theoretical increased risk of more severe coronavirus infection in people exposed to Ocrelizumab. So far real-life data does not support this. There is no mandatory requirement for shielding. However, she should strictly adhere to public health measures to reduce risk of contracting coronavirus.

She is happy to proceed with the infusion

Vaccines for Covid
Live vaccines may not be allowed with Ocrevus and other vaccines may be ineffective. Consent patients for this possibility if about to start treatment.